REPLY
8.3.2024 09:31:35 CET | Business Wire | Press release
Reply has been ranked among the leading providers of "Salesforce-related Services in Europe 2024" in the PAC Innovation RADAR, an industry study by the independent research and consulting company PAC. In the report, Reply received the highest "Best in Class" award in five industries: Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308650974/en/
The PAC INNOVATION RADAR is an instrument for the holistic evaluation of software and ICT service providers from the independent research and consulting company PAC. In the PAC INNOVATION RADAR for Salesforce-related services in Europe, Reply was awarded "Best in Class" in five sectors. (Photo: Business Wire)
The study evaluates the service performance of international software and ICT service providers implementing Salesforce projects in specific IT market segments. Based on pre-defined criteria, PAC analyzes the strategy, development, and market position of the providers and assesses their performance and competencies. For IT decision makers, the PAC RADAR provides valuable guidance in selecting the appropriate service partner.
In the Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing sectors, Reply was once again awarded "Best in Class" for its outstanding expertise and market strength in Salesforce-related services. A Salesforce partner since 2005, Reply uses the Salesforce platform to implement effective, customised cloud solutions to ensure customer success worldwide.
Thanks to its companies highly specialised in Salesforce technology, Arlanis Reply, Open Reply, Retail Reply and Power Reply, and more than 900 Salesforce certifications, Reply's competencies cover the entire Salesforce offering: Sales, Service and Marketing, B2B and B2C Commerce, Integration with Mulesoft and Analytics with Tableau. In addition, Reply's experts work with Salesforce extensions for CPQ, Field Service Lightning, Pardot and Einstein AI.
Nick Mayes, Principal Analyst at PAC, commented: "Reply is intensively exploring the market potential of generative AI for enterprises and offers strong expertise in the field of AI and Chat GPT. As a result, Reply has been able to implement innovative Salesforce GPT applications to support the needs of different industry sectors, in a very short time. Reply is leading the development of Salesforce's AI portfolio, creating new business models, products and services for enterprises.”
Filippo Rizzante, CTO of Reply, added: "Reply has an agile and integrated approach to developing cloud-native solutions. Our international teams use the latest technologies, such as AI, to optimise the customer experience and implement projects that have a proven impact on the business success of companies."
Reply has already been named an "EMEA Strategic Partner" by Salesforce in 2023. This designation is given by Salesforce to partner companies that are committed to working across regions and driving strategic issues such as generative AI together with Salesforce. Moreover, Reply is one of the few Salesforce experts in the automotive sector worldwide and has been confirmed by Salesforce as an "Automotive Cloud Launch Partner."
About PAC Innovation RADAR: "Leading Providers of Salesforce-related services in Europe 2024"
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
PAC
PAC is the leading European consulting and analyst firm for the IT industry, a content-based company with a consulting DNA. We accompany software & IT service vendors worldwide on their growth journey. Since 1976, we have helped our clients to understand market dynamics, grow their revenue, and raise their profile. PAC is an analyst-led consultancy with a team of over 100 experts across Europe. We provide market research and analysis on more than 30 countries worldwide, delivered through our portfolio pillars, Guidance, Insights, and Visibility, and our renowned SITSI® research platform. www.pacanalyst.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308650974/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom